Cargando…
Endoscopic treatment of vesicoureteral reflux: Current status
Vesicoureteral reflux (VUR) affects around 1% of all children. It carries an increased risk of febrile urinary tract infections (UTIs) and is associated with impaired renal function. Endoscopic treatment with NASHA/Dx gel (dextranomer microspheres in a stabilized hyaluronic acid-based gel of nonanim...
Autor principal: | Läckgren, Göran |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684303/ https://www.ncbi.nlm.nih.gov/pubmed/19468426 http://dx.doi.org/10.4103/0970-1591.45534 |
Ejemplares similares
-
Management of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years?
por: Läckgren, Göran, et al.
Publicado: (2021) -
Endoscopic treatment of vesicoureteral reflux in pediatric patients
por: Kim, Jong Wook, et al.
Publicado: (2013) -
Vesicoureteral reflux: surgical and endoscopic treatment
por: Capozza, Nicola, et al.
Publicado: (2007) -
Current Surgical Management of Vesicoureteral Reflux
por: Baek, Minki, et al.
Publicado: (2013) -
Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in Children
por: Cerwinka, Wolfgang H., et al.
Publicado: (2008)